BMS deal weighs on Celgene partners

Thursday’s proposed acquisition of Celgene Corp. (NASDAQ:CELG) by Bristol-Myers Squibb Co. (NYSE:BMY) put pressure on shares of Celgene partners Acceleron Pharma Inc. (NASDAQ:XLRN) and BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) on a day when U.S. stocks across the board tumbled.

Acceleron lost nearly 10% Thursday, falling $3.92 to $40.17 after the takeout was announced. Celgene reached deals with Acceleron in 2008 to develop ACVR2A antagonist sotatercept (ACE-011) and in 2011 to develop luspatercept (ACE-536), a modified ACVR2B fusion protein that inhibits several ligands in the TGF β superfamily (see "Celgene, Acceleron Planning Submissions for Luspatercept")...